What are the advantages of single‑donor (apheresis) platelets compared with pooled donor platelets?

Advantages of Single-Donor Apheresis Platelets (SDP) vs Pooled Donor Platelets

Single-donor apheresis platelets offer three primary advantages over pooled donor platelets: reduced donor exposure (theoretically lowering transfusion-transmitted infection risk), inherent leukoreduction during collection, and availability for HLA-matched transfusions in refractory patients—though clinical outcomes including bleeding, survival, and platelet increments are equivalent between the two products 1.

Key Advantages of Single-Donor Apheresis Platelets

1. Reduced Donor Exposure

• Theoretical infection risk reduction: One apheresis unit exposes the patient to a single donor, whereas pooled platelets expose patients to 4-6 donors per transfusion 1
• Important caveat: With contemporary screening and testing techniques, there is no evidence of actual differences in transfusion-transmitted infection rates in oncology patients who require multiple transfusions over their lifetime 1
• This advantage is most relevant for patients receiving only a few total transfusions 1

2. Inherent Leukoreduction

• Most current plateletpheresis procedures produce leukodepleted products during collection, containing <5 × 10⁶ leukocytes 1, 2
• Pooled whole-blood platelets require additional processing—either filtration in the blood bank or at bedside—to achieve leukoreduction 1
• This adds staff time and procedural costs to pooled products 1

3. Essential for Alloimmunized Patients

• When histocompatible platelets are required for patients refractory to random donor transfusions, single-donor platelets are the only available option for HLA-matched or cross-matched transfusions 1, 2
• This is a critical clinical indication where apheresis platelets are mandatory

Clinical Equivalence: What Does NOT Differ

Comparative studies demonstrate no differences in:

• Post-transfusion platelet increments 1
• Platelet survival 1
• Hemostatic effect 1
• Clinical bleeding outcomes 1

This means that for routine prophylactic or therapeutic transfusions, both products are equally effective at preventing or treating bleeding.

Cost Considerations

• Single-donor platelets cost 50-100% more than equivalent doses of pooled platelets 1
• Even accounting for pooling and filtering costs of whole-blood platelets, pooled products remain less expensive 1
• However, apheresis production costs have been shown to decrease over time with scale (mean 8.2% annual reduction in one study), while pooled platelet costs increased 3

Bacterial Contamination Risk: A Disadvantage of Pooled Products

• Pooled platelets from 5 whole blood units have a 5.6-fold higher risk of bacterial contamination compared to single-donor platelets (OR 5.58; 95% CI 2.60-11.98) 4
• This represents a significant safety advantage for apheresis products
• Under a theoretical scenario where 100% of platelets were pooled, an estimated 105 additional bacterial transmissions could occur annually in the US 4

Practical Algorithm for Product Selection

Use single-donor apheresis platelets when:

1. Patient is alloimmunized/refractory to random donor platelets (mandatory)
2. Minimizing donor exposure is critical (e.g., transplant candidates, patients with limited transfusion needs)
3. Leukoreduced product is required and filtration resources are limited
4. Cost is not a primary constraint

Use pooled donor platelets when:

1. Routine prophylactic or therapeutic transfusion in non-refractory patients
2. Cost containment is essential
3. Adequate filtration/leukoreduction capability exists
4. Supply of apheresis products is limited

Common Pitfalls to Avoid

• Don't assume infection risk differences exist: The theoretical advantage of reduced donor exposure has not translated to measurable differences in transfusion-transmitted infections with modern screening 1
• Check local dosing practices: Many centers now split apheresis collections into 2-3 products, so one apheresis unit may equal 4-5 (not 6-9) pooled units 1, 2
• Don't use apheresis products solely for infection prevention in heavily transfused patients: Oncology patients requiring dozens of transfusions gain no proven infection benefit 1